Anakinra‐Associated Systemic Amyloidosis

Objective To describe a 41‐year‐old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin‐1 receptor antagonist (IL‐1Ra) protein, anakinra, since the age of 28, who presented with golf‐ball size n...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & rheumatology (Hoboken, N.J.) Vol. 76; no. 1; pp. 100 - 106
Main Authors: Alehashemi, Sara, Dasari, Surendra, Metpally, Anvitha, Uss, Kat, Castelo‐Soccio, Leslie A., Heller, Theo, Kellman, Peter, Chen, Marcus Y., Ahlman, Mark, Kim, Jeff, Wargo, Susannah, Kuhns, Douglas B., Fink, Danielle, Jesus, Adriana, Martin, Paul S., Chang, Richard, Bolanos, Jonathan, Lee, Chyi‐Chia Richard, Nasr, Samih H., Goldbach‐Mansky, Raphaela, McPhail, Ellen
Format: Journal Article
Language:English
Published: Boston, USA Wiley Periodicals, Inc 01-01-2024
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To describe a 41‐year‐old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin‐1 receptor antagonist (IL‐1Ra) protein, anakinra, since the age of 28, who presented with golf‐ball size nodules at the anakinra injection sites, early satiety, new onset nephrotic syndrome in the context of normal markers of systemic inflammation. Methods Clinical history and histologic evaluation of biopsies of skin, gastric mucosa, and kidney with Congo‐red staining and proteomic evaluation of microdissected Congo red–positive amyloid deposits by liquid chromatography‐tandem mass spectrometry. Results The skin, stomach, and kidney biopsies all showed the presence of Congo red–positive amyloid deposits. Mass spectrometry‐based proteomics demonstrated that the amyloid deposits in all sites were of AIL1RAP (IL‐1Ra protein)‐type. These were characterized by high spectral counts of the amyloid signature proteins (apolipoprotein AIV, apolipoprotein E, and serum amyloid P‐component) and the amyloidogenic IL‐1Ra protein, which were present in Congo red–positive areas and absent in Congo red–negative areas. The amino acid sequence identified by mass spectrometry confirmed that the amyloid precursor protein was recombinant IL‐1Ra (anakinra) and not endogenous wild‐type IL‐1Ra. Conclusion This is the first report of iatrogenic systemic amyloidosis due to an injectable protein drug, which was caused by recombinant IL1Ra (anakinra).
Bibliography:https://onlinelibrary.wiley.com/doi/10.1002/art.42664
Supported by the Intramural Research Program at the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH.
Additional supplementary information cited in this article can be found online in the Supporting Information section
http://onlinelibrary.wiley.com/10.1002/art.42664
Author disclosures are available at
Drs. Goldbach‐Mansky and McPhail contributed equally to this work.
.
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.42664